You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)年度歸母淨利達47.35億元 同比增長29.28%

格隆匯3月23日丨復星醫藥(02196.HK)發佈年度業績公吿,截至2021年12月31日止年度,集團實現營業收入人民幣388.58億元,同比增長28.83%;實現歸屬於上市公司股東淨利潤人民幣47.35億元,同比增長29.28%;實現歸屬於上市公司股東的扣除非經常性損益的淨利潤人民幣32.77億元,同比增長20.60%;經營活動產生的現金流量淨額人民幣39.49億元,同比增長53.07%。報吿期內,集團繼續加大研發投入,全年研發投入共計人民幣49.75億元,同比增長24.28%;其中,研發費用為人民幣38.34億元,同比增加人民幣10.39億元、增長37.17%。董事會建議2021年末期股息為每股人民幣0.56元(税前)。

報吿期內,在存量品種受到藥品集採降價壓力的情況下,集團堅持踐行“4IN”戰略(創新Innovation、國際化Internationalization、整合Integration、智能化Intelligentization),整體業績依舊保持穩健增長,新產品收入佔比及中國大陸以外地區和其他國家收入佔比持續提升,收入結構持續優化。2021年,創新研發加速落地,奕凱達(阿基侖賽注射液)、斯魯利單抗注射液等多款創新產品陸續獲批或進入關鍵臨牀╱審批階段。海外能力持續強化,以美國為第二總部,基本形成研產銷全覆蓋的全球化業務格局。對集團各業務條線及組織架構的整合梳理持續推進,實現各板塊分線聚焦。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account